An industry group representing companies developing cell and gene therapies is pushing the HHS Office of Inspector General (OIG) to adopt safe harbor provisions under the Federal Anti-Kickback Statute (AKS) that would allow companies to provide more assistance to patients, while a bill before the House Energy & Commerce Committee would legally establish a similar policy. Alliance for Regenerative Medicine (ARM) sent a letter to OIG on Feb. 2 asking the office to establish safe harbor provisions that would give...